NHS drugs spend should be linked to patient value and value for money, according to a report by the Office of Fair Trading.

The report recommends that the current scheme where companies can set their own prices should be replaced by one in which prices are set according to therapeutic benefit to patients.

Read the report here

NHS drugs spend should be linked to patient value and value for money, according to a report by the Office of Fair Trading.

The report recommends that the current scheme where companies can set their own prices should be replaced by one in which prices are set according to therapeutic benefit to patients.

Read the report here